Therefore, new methods are needed to aid in the interpretation of uncertain variants as well as to increase the detection rate of BRCA1 and BRCA2 germline mutations for genetic counseling and clinical management of familial breast cancers. This evidence concerns the gene BRCA2 and breast carcinoma.